Sentry Investment Management LLC Sells 225 Shares of Stryker Co. (NYSE:SYK)

Sentry Investment Management LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,380 shares of the medical technology company’s stock after selling 225 shares during the period. Sentry Investment Management LLC’s holdings in Stryker were worth $497,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pine Valley Investments Ltd Liability Co grew its holdings in shares of Stryker by 6.7% during the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 2,324 shares of the medical technology company’s stock worth $839,000 after purchasing an additional 146 shares in the last quarter. Addison Advisors LLC lifted its position in Stryker by 1.9% during the fourth quarter. Addison Advisors LLC now owns 4,043 shares of the medical technology company’s stock valued at $1,456,000 after purchasing an additional 75 shares during the last quarter. BankPlus Trust Department purchased a new position in Stryker in the 4th quarter worth approximately $33,000. W.G. Shaheen & Associates DBA Whitney & Co increased its holdings in shares of Stryker by 1.8% in the 4th quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 29,240 shares of the medical technology company’s stock worth $10,528,000 after buying an additional 519 shares during the last quarter. Finally, Edge Capital Group LLC raised its position in shares of Stryker by 7.1% during the 4th quarter. Edge Capital Group LLC now owns 1,144 shares of the medical technology company’s stock valued at $412,000 after buying an additional 76 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SYK. Wells Fargo & Company upped their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. BTIG Research raised their price objective on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Truist Financial upped their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Finally, Barclays lifted their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Trading Up 1.4 %

NYSE SYK opened at $388.11 on Tuesday. The stock has a market cap of $148.09 billion, a P/E ratio of 50.01, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a 50 day simple moving average of $378.38 and a two-hundred day simple moving average of $369.78. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business earned $3.46 earnings per share. On average, analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.